Volume 5 Supplement 1
Therapeutic management of intestinal fibrosis induced by radiation therapy: from molecular profiling to new intervention strategies et vice et versa
© Hamama et al; licensee BioMed Central Ltd. 2012
Published: 6 June 2012
Chronic toxicities of locoregional and systemic oncological treatments commonly develop in long-term cancer survivors. Amongst these toxicities, post-radiotherapeutic complications alter patient's quality of life. Reduction of exposure of normal tissues can be achieved by optimization of radiotherapy. Furthermore, understanding of the fibrogenic mechanisms has provided targets to prevent, mitigate, and reverse late radiation-induced damages. This mini-review shows how (i) global molecular studies using gene profiling can provide tools to develop new intervention strategies and (ii) how successful clinical trials, conducted in particular with combined pentoxifylline-vitamin E, can take benefice of biological and molecular evidences to improve our understanding of fibrogenic mechanisms, enhance the robustness of proposed treatments, and lead ultimately to better treatments for patient's benefice.
Therapeutic management of cancer improved during the past decade and is characterized today by a significant increase in patient's survival rates. Although effective on cure rates, both locoregional and systemic oncological treatments present some concerns related to development of chronic toxicities that alter patient's quality of life, while results of combined therapies suggest that normal tissue toxicity will become a major concern within the next years. Amongst these toxicities, radiation enteropathy is a significant delayed side effect of lumbar and pelvic radiotherapy.
The risk, severity and nature of these radiation-induced toxicities depend on several factors including radiotherapy-related factors (total dose, dose per fraction and volume exposure) and patient-related factors (comorbidities) . Accordingly, a real effort has been made to reduce normal tissue exposure by ballistic and imaging optimization of radiotherapy. Besides technological tools, understanding the fibrogenic mechanisms and targeting profibrotic factors has provided alternate and promising approaches to prevent, mitigate or even reverse late radiation-induced damages [1, 2].
If today's clinical practice always aims to limit aggravating factors, current management of radiation-induced damages involves : (i) anti-inflammatory treatments including corticosteroids; (ii) vascular therapy including pentoxifylline (PTX) or hyperbaric oxygen; (iii) antioxidant treatment including superoxide dismutase in the nineties and then combined pentoxifylline-vitamin E (PTX-VitE) in the last decade.
The first part of this mini-review shows how global molecular studies using gene profiling can provide tools to develop new intervention strategies with old molecules or new compounds. The second part shows how successful clinical research done with well-known but low potent old drugs takes benefice of biological and molecular evidences to improve its robustness for patient's benefice.
From molecular profiling to new intervention strategies
Cellular and molecular mechanisms involved in the persistence of radiation fibrosis
In all irradiated tissues and especially when vital organs like the heart, lung or intestine are affected , the most concerning aspect of radiation fibrosis is its progressive and seemingly irreversible evolution. Thus, the development of curative anti-fibrotic strategies is nowadays highly anticipated by both patients and physicians . Definition of new biologically-based anti-fibrotic strategies is therefore an attractive option to be achieved by characterization of the cellular and molecular mechanisms involved in the persistence of radiation fibrosis.
In human radiation enteropathy, fibrosis is the main histopathological hallmark . Fibrosis contributes to the loss of intestinal compliance and impaired intestinal function and we showed that it was associated with heavy deposition of Connective Tissue Growth Factor (CTGF/CCN2) . CTGF gene regulation is known to be under the control of TGF-β via a Smad consensus sequence and TGF-β RE/BCE-1 binding sites located in the CTGF promoter region [8, 9]. We showed that, surprisingly, TGF-β1 expression in fibrotic area was low during the onset of radiation enteropathy . The molecular basis of this paradox was investigated using (i) a high-throughput biological approach by cDNA array profiling and (ii) a classical biochemical approach with recombinant TGF-β1 and CTGF. These studies were performed with unique and physiologically relevant cell models, employing primary smooth muscle cells and sub-epithelial myofibroblasts derived from radiation enteropathy. These cells mimic fibrosis in vitro, as they maintain their fibrogenic features in long term culture (6-8 passages) i.e. altered contractile function, modification of the actin cytoskeleton and increased secretory activity [10, 11].
The comprehensive cDNA approach showed activation of the Rho/ROCK pathway . Further functional in vitro experiments showed that this intercellular signaling pathway controls CTGF expression in intestinal smooth muscle cells and in subepithelial myofibroblasts derived from radiation enteropathy [10, 13]. In addition, our gene profiling studies showed that radiation enteropathy was associated with a global deregulation of the extracellular matrix remodeling with increased ECM deposition, MMPs and TIMPs activity . Whether this dynamic remodeling process was the cause or the consequence of the phenotypic alteration of the resident mesenchymal cells is currently under investigation.
Cell response to increasing concentrations of recombinant TGF-β1 was investigated. Activation of cell-specific signaling pathways by low TGF-β1 concentrations was demonstrated with a prominent activation of the Rho/ROCK pathway in fibrosis-derived cells, whereas the Smad pathway was predominantly activated in normal cells. This differential fibrogenic response identified in normal versus fibrosis-derived cells opened new therapeutic opportunities for targeted anti-fibrotic therapy. In addition, we showed that recombinant CTGF was able to trigger its auto-induction in fibrosis-derived cells, an effect which was further enhanced by TGF-β1. These results thus identify specific and combinatorial roles of low TGF-β1 doses and CTGF for the maintenance of tissue fibrosis .
From physiopathological mechanisms to clinical transfer
Searching for anti-fibrotic treatment using molecular targets lead to the development of targeted drugs. Amongst them anti-CTGF antibody , imatinib (anti-PDGF antibody) [25–27], statin (Rho/Rock-inhibitors) [20–23, 28] have demonstrated efficacy in pre-clinical studies and need now to be validated in clinical trials. Two targeted drugs have recently showed interesting results in recent trials: the small molecule inhibitor of TGF-β1, pirfenidone, and the tyrosine kinase inhibitor, BIBF 1120. Both of them halt progression of idiopathic pulmonary fibrosis [29, 30]. Still others, such as combined pentoxifylline-vitamin E has a proven clinical efficacy with an unknown mechanism of action [31–38].
From clinical trials to understanding the molecular mechanism
In the nineties an antioxidant compound, the liposomal Cu/Zn superoxide dismutase (SOD), was the first drug to half reduce established radiation fibrosis in patients and experimental models (reviewed in ). Biological studies showed that SOD inhibited TGF-β1 and TIMPs and lead to a subsequent reversion of the myofibroblastic phenotype in vitro [39, 40]. Later, Delanian et al. showed that combined PTX-Vit.E administered to patients, half reduced superficial radiation fibrosis in 6 months . Results were confirmed in a randomized clinical trial  and by long-term clinical results (3 years) . A first experimental study using skin fibrosis in pig as model showed that the histopathological recovery after PTX/VitE treatment was associated with significant reduction of TGF-β1 deposition . Since then, numerous clinical trials were successful and showed improvement of osteoradionecrosis , superficial fibrosis , proctitis/enteritis , pelvic complications , uterine fibro-atrophy [35, 42]. Moreover, combined PTX-Vit.E in rat experiment had beneficial effects on radiation-induced myocardial fibrosis and left ventricular function . Recent report using a triple combination PENTOCLO: PTX-VitE and clodronate; a biphosphonate active against macrophages also allows successful healing of severe osteoradionecrosis  and reduction of neurological symptoms associated with radiation-induced plexopathies . The efficacy of this triple combination is currently validated in a phase III randomized clinical trial that has started at Saint Louis Hospital for radiation-induced plexitis (support by the French Ministry of Health, PHRC 2009). Therefore, understanding the molecular mechanism of PTX-Vit.E combination solicit much interest for better understanding of radiation-induced fibrosis, to improve treatment robustness and will pave the way toward new more efficient treatments.
Vitamin E (α-tocopherol) is an antioxidant drug known to modulate the expression of several genes such as ICAM-1 integrins and PPAR-gamma . α-tocopherol was reported to decrease the expression of genes known to be involved in the fibrotic process such as (MMP-1) in human skin fibroblast , and IL-1β in THP-1 cells . In mice, D-α-tocopherol supplementation decreased collagen mRNA in the liver by 70% . In type 2 diabetic patients, α-tocopherol supplementation lowered plasma levels of PAI-1 and P-selectin . In other case, α-tocopherol induces the expression of CTGF in human smooth muscle cells while neither β-tocopherol nor N-acetylcysteine do . It was suggested that this modulation of CTGF was unique as it was not triggered by structurally related antioxidant molecules, suggesting occurrence of a non-antioxidant mechanism in the transcriptional regulation of several genes.
Pentoxifylline, PTX is a methylxanthine derivative used to treat vascular disease such as intermittent claudication. In vivo, it has been reported to have anti-TNF-α effect, increase erythrocyte flexibility, vasodilate, and inhibit inflammatory reactions. In vitro studies have indicated that PTX has also antioxidant properties , inhibits human dermal fibroblast proliferation and extracellular matrix production [53–55] and increases collagenase activity . However, the doses of pentoxifylline required to produce these effects in vitro are high, and reached 1000 μg/ml in some cases  rendering in vivo use of PTX unsuitable. In addition, PTX is known as a non-specific phosphodiesterases inhibitor that subsequently increases intracellular levels of cAMP. Like other cAMP elevating agents PTX could activate protein kinase A (PKA) which would phosphorylate transcription factors, such as cAMP response element binding protein (CREB). Activated CREB recruits the coactivators CBP and P300 that also act as transcriptional co-activators for SMADs [56, 57]. Therefore, the sequestration of CBP/P300 by activated CREB could inhibit SMAD-dependent transcription  and constitute one molecular mechanism to explain PTX anti-fibrotic action that remains to be demonstrated in vivo. For example, in a model RIF-induced in pigs no clinical or histological changes were observed in RIF after 6 months of treatment with PTX alone using maximum tolerated dose . Extrapolation from in vitro studies would however suggest that higher concentration of PTX would be required to achieve effective suppression of collagen synthesis or to increase collagenase activity. Used at this dosage, PTX might be extremely toxic and suggests that administration of PTX alone does not constitute an anti-fibrotic treatment.
From molecular profiling to clinical trials in a bottom-up manner or from the clinical trials to the molecular understanding in a top-down approach, these studies have optimized our understanding of radiation-induced fibrogenesis. Combining these information could ultimately lead to improve management of fibrosis.
In a model of intestinal fibrosis, Statins act principally via inhibition of Rho/Rock pathway decreasing subsequently the expression of CTGF. In contrast, combined pentoxifylline-trolox inhibits TGF-β1 pathway while it appears to have no influence on Rho/Rock pathway. Therefore combining these two medications to generate a more efficient triple therapy seemed a logical follow up. While emerging new combinations might be promising, heavy investigations are needed to prove their safety and efficacy over already solid candidates as Statins or combined pentoxifylline-vitamin E.
This article has been published as part of Fibrogenesis & Tissue Repair Volume 5 Supplement 1, 2012: Proceedings of Fibroproliferative disorders: from biochemical analysis to targeted therapies. The full contents of the supplement are available online at http://www.fibrogenesis.com/supplements/5/S1.
- Delanian S, Lefaix JL: The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol. 2004, 73 (2): 119-131. 10.1016/j.radonc.2004.08.021.View ArticlePubMedGoogle Scholar
- Gervaz P, Morel P, Vozenin-Brotons MC: Molecular aspects of intestinal radiation-induced fibrosis. Curr Mol Med. 2009, 9 (3): 273-280. 10.2174/156652409787847164.View ArticlePubMedGoogle Scholar
- Delanian S, Lefaix JL: Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol. 2007, 17 (2): 99-107. 10.1016/j.semradonc.2006.11.006.View ArticlePubMedGoogle Scholar
- Hauer-Jensen M, Wang J, Denham JW: Bowel injury: current and evolving management strategies. Semin Radiat Oncol. 2003, 13 (3): 357-371.PubMedGoogle Scholar
- Anscher MS: The irreversibility of radiation-induced fibrosis: fact or folklore?. J Clin Oncol. 2005, 23 (34): 8551-8552. 10.1200/JCO.2005.03.6194.View ArticlePubMedGoogle Scholar
- Fajardo LF: The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol. 2005, 44 (1): 13-22. 10.1080/02841860510007440.View ArticlePubMedGoogle Scholar
- Vozenin-Brotons MC, Milliat F, Sabourin JC, de Gouville AC, Francois A, Lasser P, Morice P, Haie-Meder C, Lusinchi A, Antoun S, et al: Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression. Int J Radiat Oncol Biol Phys. 2003, 56 (2): 561-572. 10.1016/S0360-3016(02)04601-1.View ArticlePubMedGoogle Scholar
- Grotendorst GR, Okochi H, Hayashi N: A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ. 1996, 7 (4): 469-480.PubMedGoogle Scholar
- Leask A, Holmes A, Black CM, Abraham DJ: Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem. 2003, 278 (15): 13008-13015. 10.1074/jbc.M210366200.View ArticlePubMedGoogle Scholar
- Bourgier C, Haydont V, Milliat F, Francois A, Holler V, Lasser P, Bourhis J, Mathe D, Vozenin-Brotons MC: Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut. 2005, 54 (3): 336-343. 10.1136/gut.2004.051169.PubMed CentralView ArticlePubMedGoogle Scholar
- Haydont V, Mathe D, Bourgier C, Abdelali J, Aigueperse J, Bourhis J, Vozenin-Brotons MC: Induction of CTGF by TGF-beta1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. Radiother Oncol. 2005, 76 (2): 219-225. 10.1016/j.radonc.2005.06.029.View ArticlePubMedGoogle Scholar
- Vozenin-Brotons MC, Milliat F, Linard C, Strup C, Francois A, Sabourin JC, Lasser P, Lusinchi A, Deutsch E, Girinsky T, et al: Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization. Radiat Res. 2004, 161 (3): 299-311. 10.1667/RR3128.View ArticlePubMedGoogle Scholar
- Haydont V, Bourgier C, Vozenin-Brotons MC: Rho/ROCK pathway as a molecular target for modulation of intestinal radiation-induced toxicity. Br J Radiol. 2007, 80 (Spec No 1): S32-40.View ArticlePubMedGoogle Scholar
- Strup-Perrot C, Mathe D, Linard C, Violot D, Milliat F, Francois A, Bourhis J, Vozenin-Brotons MC: Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis. Am J Physiol Gastrointest Liver Physiol. 2004, 287 (4): G875-885. 10.1152/ajpgi.00088.2004.View ArticlePubMedGoogle Scholar
- Haydont V, Riser BL, Aigueperse J, Vozenin-Brotons MC: Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: a role for CCN2 and low concentration of TGF-beta1. Am J Physiol Cell Physiol. 2008, 294 (6): C1332-1341. 10.1152/ajpcell.90626.2007.View ArticlePubMedGoogle Scholar
- Ridley AJ: Rho GTPases and cell migration. J Cell Sci. 2001, 114 (Pt 15): 2713-2722.PubMedGoogle Scholar
- Vieu E, Hernandez N: Actin's latest act: polymerizing to facilitate transcription?. Nat Cell Biol. 2006, 8 (7): 650-651. 10.1038/ncb0706-650.View ArticlePubMedGoogle Scholar
- Boerma M, Fu Q, Wang J, Loose DS, Bartolozzi A, Ellis JL, McGonigle S, Paradise E, Sweetnam P, Fink LM, et al: Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis. 2008, 19 (7): 709-718. 10.1097/MBC.0b013e32830b2891.PubMed CentralView ArticlePubMedGoogle Scholar
- Greenwood J, Steinman L, Zamvil SS: Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006, 6 (5): 358-370. 10.1038/nri1839.View ArticlePubMedGoogle Scholar
- Haydont V, Gilliot O, Rivera S, Bourgier C, Francois A, Aigueperse J, Bourhis J, Vozenin-Brotons MC: Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement or tumor protection. Int J Radiat Oncol Biol Phys. 2007, 68 (5): 1471-1482. 10.1016/j.ijrobp.2007.03.044.View ArticlePubMedGoogle Scholar
- Wang J, Boerma M, Fu Q, Kulkarni A, Fink LM, Hauer-Jensen M: Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys. 2007, 68 (5): 1483-1490. 10.1016/j.ijrobp.2007.03.036.PubMed CentralView ArticlePubMedGoogle Scholar
- Williams JP, Hernady E, Johnston CJ, Reed CM, Fenton B, Okunieff P, Finkelstein JN: Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res. 2004, 161 (5): 560-567. 10.1667/RR3168.View ArticlePubMedGoogle Scholar
- Monceau V, Pasinetti N, Schupp C, Pouzoulet F, Opolon P, Vozenin MC: Modulation of the Rho/ROCK pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity. Curr Drug Targets. 2010, 11 (11): 1395-1404.View ArticlePubMedGoogle Scholar
- Ikawa Y, Ng PS, Endo K, Kondo M, Chujo S, Ishida W, Shirasaki F, Fujimoto M, Takehara K: Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-beta-induced mouse fibrosis. J Cell Physiol. 2008, 216 (3): 680-687. 10.1002/jcp.21449.View ArticlePubMedGoogle Scholar
- Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE, et al: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005, 201 (6): 925-935. 10.1084/jem.20041393.PubMed CentralView ArticlePubMedGoogle Scholar
- Vuorinen K, Gao F, Oury TD, Kinnula VL, Myllarniemi M: Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res. 2007, 33 (7): 357-373. 10.1080/01902140701634827.PubMed CentralView ArticlePubMedGoogle Scholar
- Gordon JK, Spiera RF: Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Curr Opin Rheumatol. 2010, 22 (6): 690-695. 10.1097/BOR.0b013e32833f1105.View ArticlePubMedGoogle Scholar
- Gaugler MH, Vereycken-Holler V, Squiban C, Vandamme M, Vozenin-Brotons MC, Benderitter M: Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res. 2005, 163 (5): 479-487. 10.1667/RR3302.View ArticlePubMedGoogle Scholar
- Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster L, Sahn SA, Szwarcberg J, et al: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011, 377 (9779): 1760-1769. 10.1016/S0140-6736(11)60405-4.View ArticlePubMedGoogle Scholar
- Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, et al: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011, 365 (12): 1079-1087. 10.1056/NEJMoa1103690.View ArticlePubMedGoogle Scholar
- Delanian S, Balla-Mekias S, Lefaix JL: Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. J Clin Oncol. 1999, 17 (10): 3283-3290.PubMedGoogle Scholar
- Delanian S, Porcher R, Balla-Mekias S, Lefaix JL: Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol. 2003, 21 (13): 2545-2550. 10.1200/JCO.2003.06.064.View ArticlePubMedGoogle Scholar
- Delanian S, Depondt J, Lefaix JL: Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck. 2005, 27 (2): 114-123. 10.1002/hed.20121.View ArticlePubMedGoogle Scholar
- Delanian S, Porcher R, Rudant J, Lefaix JL: Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol. 2005, 23 (34): 8570-8579. 10.1200/JCO.2005.02.4729.View ArticlePubMedGoogle Scholar
- Letur-Konirsch H, Guis F, Delanian S: Uterine restoration by radiation sequelae regression with combined pentoxifylline-tocopherol: a phase II study. Fertil Steril. 2002, 77 (6): 1219-1226. 10.1016/S0015-0282(02)03120-5.View ArticlePubMedGoogle Scholar
- Haddad P, Kalaghchi B, Amouzegar-Hashemi F: Pentoxifylline and vitamin E combination for superficial radiation-induced fibrosis: a phase II clinical trial. Radiother Oncol. 2005, 77 (3): 324-326. 10.1016/j.radonc.2005.09.014.View ArticlePubMedGoogle Scholar
- Hille A, Christiansen H, Pradier O, Hermann RM, Siekmeyer B, Weiss E, Hilgers R, Hess CF, Schmidberger H: Effect of pentoxifylline and tocopherol on radiation proctitis/enteritis. Strahlenther Onkol. 2005, 181 (9): 606-614. 10.1007/s00066-005-1390-y.View ArticlePubMedGoogle Scholar
- Gothard L, Cornes P, Brooker S, Earl J, Glees J, Hall E, Peckitt C, Tait D, Yarnold J: Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. Radiother Oncol. 2005, 75 (3): 334-341. 10.1016/j.radonc.2005.02.002.View ArticlePubMedGoogle Scholar
- Delanian S, Martin M, Bravard A, Luccioni C, Lefaix JL: Cu/Zn superoxide dismutase modulates phenotypic changes in cultured fibroblasts from human skin with chronic radiotherapy damage. Radiother Oncol. 2001, 58 (3): 325-331. 10.1016/S0167-8140(00)00332-7.View ArticlePubMedGoogle Scholar
- Vozenin-Brotons MC, Sivan V, Gault N, Renard C, Geffrotin C, Delanian S, Lefaix JL, Martin M: Antifibrotic action of Cu/Zn SOD is mediated by TGF-beta1 repression and phenotypic reversion of myofibroblasts. Free Radic Biol Med. 2001, 30 (1): 30-42. 10.1016/S0891-5849(00)00431-7.View ArticlePubMedGoogle Scholar
- Lefaix JL, Delanian S, Vozenin MC, Leplat JJ, Tricaud Y, Martin M: Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: an experimental study. Int J Radiat Oncol Biol Phys. 1999, 43 (4): 839-847. 10.1016/S0360-3016(98)00419-2.View ArticlePubMedGoogle Scholar
- Ledee-Bataille N, Olivennes F, Lefaix JL, Chaouat G, Frydman R, Delanian S: Combined treatment by pentoxifylline and tocopherol for recipient women with a thin endometrium enrolled in an oocyte donation programme. Hum Reprod. 2002, 17 (5): 1249-1253. 10.1093/humrep/17.5.1249.View ArticlePubMedGoogle Scholar
- Boerma M, Roberto KA, Hauer-Jensen M: Prevention and treatment of functional and structural radiation injury in the rat heart by pentoxifylline and alpha-tocopherol. Int J Radiat Oncol Biol Phys. 2008, 72 (1): 170-177. 10.1016/j.ijrobp.2008.04.042.PubMed CentralView ArticlePubMedGoogle Scholar
- Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL: Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys. 2011, 80 (3): 832-839. 10.1016/j.ijrobp.2010.03.029.View ArticlePubMedGoogle Scholar
- Delanian S, Lefaix JL, Maisonobe T, Salachas F, Pradat PF: Significant clinical improvement in radiation-induced lumbosacral polyradiculopathy by a treatment combining pentoxifylline, tocopherol, and clodronate (Pentoclo). J Neurol Sci. 2008, 275 (1-2): 164-166. 10.1016/j.jns.2008.08.004.View ArticlePubMedGoogle Scholar
- Azzi A, Gysin R, Kempna P, Munteanu A, Negis Y, Villacorta L, Visarius T, Zingg JM: Vitamin E mediates cell signaling and regulation of gene expression. Ann N Y Acad Sci. 2004, 1031: 86-95. 10.1196/annals.1331.009.View ArticlePubMedGoogle Scholar
- Ricciarelli R, Maroni P, Ozer N, Zingg JM, Azzi A: Age-dependent increase of collagenase expression can be reduced by alpha-tocopherol via protein kinase C inhibition. Free Radic Biol Med. 1999, 27 (7-8): 729-737. 10.1016/S0891-5849(99)00007-6.View ArticlePubMedGoogle Scholar
- Akeson AL, Woods CW, Mosher LB, Thomas CE, Jackson RL: Inhibition of IL-1 beta expression in THP-1 cells by probucol and tocopherol. Atherosclerosis. 1991, 86 (2-3): 261-270. 10.1016/0021-9150(91)90222-O.View ArticlePubMedGoogle Scholar
- Chojkier M, Houglum K, Lee KS, Buck M: Long- and short-term D-alpha-tocopherol supplementation inhibits liver collagen alpha1(I) gene expression. Am J Physiol. 1998, 275 (6 Pt 1): G1480-1485.PubMedGoogle Scholar
- Devaraj S, Chan AV, Jialal I: alpha-Tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients. Diabetes Care. 2002, 25 (3): 524-529. 10.2337/diacare.25.3.524.View ArticlePubMedGoogle Scholar
- Villacorta L, Graca-Souza AV, Ricciarelli R, Zingg JM, Azzi A: Alpha-tocopherol induces expression of connective tissue growth factor and antagonizes tumor necrosis factor-alpha-mediated downregulation in human smooth muscle cells. Circ Res. 2003, 92 (1): 104-110. 10.1161/01.RES.0000049103.38175.1B.View ArticlePubMedGoogle Scholar
- Horvath B, Marton Z, Halmosi R, Alexy T, Szapary L, Vekasi J, Biro Z, Habon T, Kesmarky G, Toth K: In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol. 2002, 25 (1): 37-42. 10.1097/00002826-200201000-00007.View ArticlePubMedGoogle Scholar
- Berman B, Duncan MR: Pentoxifylline inhibits normal human dermal fibroblast in vitro proliferation, collagen, glycosaminoglycan, and fibronectin production, and increases collagenase activity. J Invest Dermatol. 1989, 92 (4): 605-610. 10.1111/1523-1747.ep12712140.View ArticlePubMedGoogle Scholar
- Berman B, Duncan MR: Pentoxifylline inhibits the proliferation of human fibroblasts derived from keloid, scleroderma and morphoea skin and their production of collagen, glycosaminoglycans and fibronectin. Br J Dermatol. 1990, 123 (3): 339-346. 10.1111/j.1365-2133.1990.tb06294.x.View ArticlePubMedGoogle Scholar
- Duncan MR, Hasan A, Berman B: Pentoxifylline, pentifylline, and interferons decrease type I and III procollagen mRNA levels in dermal fibroblasts: evidence for mediation by nuclear factor 1 down-regulation. J Invest Dermatol. 1995, 104 (2): 282-286. 10.1111/1523-1747.ep12612819.View ArticlePubMedGoogle Scholar
- Janknecht R, Wells NJ, Hunter T: TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev. 1998, 12 (14): 2114-2119. 10.1101/gad.12.14.2114.PubMed CentralView ArticlePubMedGoogle Scholar
- Pouponnot C, Jayaraman L, Massague J: Physical and functional interaction of SMADs and p300/CBP. J Biol Chem. 1998, 273 (36): 22865-22868. 10.1074/jbc.273.36.22865.View ArticlePubMedGoogle Scholar
- Schiller M, Verrecchia F, Mauviel A: Cyclic adenosine 3',5'-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism. Oncogene. 2003, 22 (55): 8881-8890. 10.1038/sj.onc.1206871.View ArticlePubMedGoogle Scholar
- Laurent C, Pouget JP, Voisin P: Modulation of DNA damage by pentoxifylline and alpha-tocopherol in skin fibroblasts exposed to Gamma rays. Radiat Res. 2005, 164 (1): 63-72. 10.1667/RR3383.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.